Melevodopa

HCID 23497CAS 7101-51-1

Teilstruktursuche Ähnliche Strukturen suchen

Grundinformationen

Standard-SMILES: COC(=O)[C@@H](N)Cc1ccc(O)c(O)c1
InChIKey: XBBDACCLCFWBSI-ZETCQYMHSA-N
Summenformel: C10H13NO4
Durchschnittliche Molmasse: 211,21 g/mol
Monoisotopische Masse: 211,0844579

Überblick

Melevodopa is a tyrosine derivative.

Namen und Bezeichner

Bevorzugter Name: Melevodopa
IUPAC: methyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate
Englischer Name: (S)-2-Amino-3-(3,4-dihydroxy-phenyl)-propionic acid methyl ester
Summenformel: C10H13NO4
Molmasse: 211.21

Namen und Synonyme

Melevodopa7101-51-1L-Dopa methyl esterLevodopa methyl esterlevometmethyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoateChf-1301M30686U4X4DTXSID9048433methyl L-dopamelevodopumRefChem:156332

Weitere Namen anzeigen

DOPA-METHYLESTERMethyl 3-hydroxy-L-tyrosinatemethyl (S)-2-amino-3-(4-chlorophenyl)propanoate hydrochloride(S)-2-Amino-3-(3,4-dihydroxy-phenyl)-propionic acid methyl ester

DTXCID5028407N04BA04Melevodopa [INN](S)-Methyl 2-amino-3-(3,4-dihydroxyphenyl)propanoate3-Hydroxy-L-tyrosine methyl esterL-Tyrosine, 3-hydroxy-, methyl ester(-)-3,4-Dihydroxy-L-phenylalanine, methyl esterMelevodopa (INN)

Datenbank-Bezeichner

CAS: 7101-51-1
PubChem CID: 23497
DTXSID: DTXSID9048433
ChEMBL: CHEMBL1328898
ChEBI: CHEBI:134880
UNII: M30686U4X4
Nikkaji: J33.787K

Eigenschaften

Berechnete Struktureigenschaften

XLogP: -0,2
Polarare Oberfläche (TPSA): 92,8 Å²
H-Brücken-Donoren: 3
H-Brücken-Akzeptoren: 5
Frei drehbare Bindungen: 4
Schwere Atome: 15
Formalladung: 0
Komplexität: 221

Physikochemische Eigenschaften

Siedepunkt: 350.89 °C · 350.89°C (rough estimate)
Dichte: 1.2545 · 1.2545 (rough estimate)
Brechungsindex: 1.515 · 1.5150 (estimate)
storage temp.: 2 · 2-8°C
Aggregatzustand: solid
pka: 9.67 · 9.67±0.20(Predicted)
Farbe: White

Sicherheit und Regulatorisches

Sicherheitsdaten

hs_code: 2922500090

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

N - Nervous system

QN - Nervous system

MeSH Pharmacological ClassificationAgents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.

Anwendungen · 1 Eintrag

BeschreibungCHF-1301 was launched as an injection in Italy for the treatment of patients with Parkinson's disease, particularly those with complications in their clinical responses. CHF-1301 is the methyl ester of L-Dopa (levodopa), the immediate precursor of dopamine. Thus, this prodrug is more soluble in water at physiological pH, better absorbed and slowly transformed into levodopa in vivo; it consequently improves the duration of action and prevents the rapid fluctuations in response or involontary movements (dyskinesia) observed during chronic treatment with levodopa. In patients with a delayed effect of levodopa (on-phenomenon) or a severe resistance to L-Dopa (off-phenomenon), CHF- 1301 significantly improves the onset and the stability of the'response.